Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02776059 · ClinicalTrials.gov registry record · Phase 2
Pegfilgrastim in Patients With Alcoholic Hepatitis
A Phase 2 study, sponsored by Timothy Morgan, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT02776059: Completed Phase 2 study, sponsored by Timothy Morgan, MD.
NCT02776059 is a Phase 2 study that has completed, run by Timothy Morgan, MD. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02776059, a Phase 2 study, has completed, sponsored by Timothy Morgan, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is a multi-center, prospective, randomized trial of standard of care vs. standard of care + pegfilgrastim (Neulasta®) among patients with a clinical diagnosis of alcoholic hepatitis and DF≥32.
Primary Outcome
The primary outcome will be survival at Day 90. Assuming a fixed sample size of 70 patients (35 per arm), a one-sided z-test will have 81.6% power to detect a 25% improvement in survival proportions between arms, with survival in the standard of care arm at 65%.
Interventions
- DRUG Standard of care
- DRUG Standard of care + pegfiltrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2017-01-21 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 2 |
What the finished NCT02776059 record still lists
NCT02776059 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 2 interventions - of which Standard of care is the first listed.
NCT02776059 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02776059 about?
NCT02776059 is a clinical study titled "Pegfilgrastim in Patients With Alcoholic Hepatitis". This is a multi-center, prospective, randomized trial of standard of care vs. standard of care + pegfilgrastim (Neulasta®) among patients with a clinical diagnosis of alcoholic hepatitis and DF≥32.
What is the current status of trial NCT02776059?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2017-01-21. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT02776059?
The interventions under investigation include: Standard of care (DRUG), Standard of care + pegfiltrastim (DRUG).
Who is sponsoring clinical trial NCT02776059?
This trial is sponsored by Timothy Morgan, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02776059's enrollment target sits among peer trials
34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI